Absence of JH2 domain mutation of the tyrosine kinase JAK2 in renal cell carcinomas

By Zhao Jianming   Moch Holger  

Acta Oncologica, Vol. 47, Iss. 3, 2007-07 ,pp. : 474-476

Informa Healthcare

Access to resources Recommend Favorite

Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer

By Kinch Michael   Carles-Kinch Kelly  

Clinical and Experimental Metastasis, Vol. 20, Iss. 1, 2003-02 ,pp. : 59-68

Springer Publishing Company

Access to resources Recommend Favorite

Systemic therapy of kidney cancer: tyrosine kinase inhibitors, antiangiogenesis or IL-2?

By Kirkali Ziya   Tüüzel Emre  

Future Oncology, Vol. 5, Iss. 6, 2009-08 ,pp. : 871-888

Future Medicine

Access to resources Recommend Favorite

Transfection of Human Ovarian Cancer Cells with the HER-2/ neu Receptor Tyrosine Kinase Induces a Selective Increase in PTP-H1, PTP-1B, and PTP-alpha Expression

By Wiener J.R.   Kassim S.K.   Yu Y.   Mills G.B.   Bast Jr R.C.  

Gynecologic Oncology, Vol. 61, Iss. 2, 1996-05 ,pp. : 233-240

Academic Press

Access to resources Recommend Favorite

AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib

By Maiello Monica   D’Alessio Amelia   Luca Antonella   Carotenuto Adele   Rachiglio Anna   Napolitano Maria   Cito Letizia   Guzzo Antonella   Normanno Nicola  

Breast Cancer Research and Treatment, Vol. 102, Iss. 3, 2007-05 ,pp. : 275-282

Springer Publishing Company

Access to resources Recommend Favorite